尤瑞克林治疗急性进展性脑梗死的临床疗效及安全性分析(1)
[摘要] 目的 探索分析应用尤瑞克林治疗急性进展性脑梗死所产生的临床效果及其安全性。 方法 选择我院收治的180例急性进展性脑梗死患者作为研究对象并进行分组研究，对照组90例应用常规方式进行治疗，研究组90例在常规治疗的基础上加用尤瑞克林。将两组患者的临床疗效及其安全性进行对比。 结果 两组研究对象治疗前神经功能缺损症状(NIHSS)评分以及日常生活活动能力(ADL)评分不存在显著性差异(P>0.05)；研究组治疗后NIHSS评分明显低于对照组，但该组患者的ADL评分则明显高于对照组(P<0.05)。研究组治疗总有效率为91.11%，明显超过对照组的73.33%(P<0.05)。两组患者均有5%左右的血压降低、恶心等不良反应发生率，经对症治疗后有效缓解(P>0.05)。 结论 针对急性进展性脑梗死患者进行治疗，应用尤瑞克林，能够有效纠正患者神经功能缺损症状，提升其日常活动水平，疗效显著，不良反应少，安全性高，具有极大的推广应用价值。
[关键词] 急性进展性脑梗死；尤瑞克林；临床疗效；安全性
, http://www.100md.com
[中图分类号] R743.33 [文献标识码] B [文章编号] 2095-0616(2015)13-61-04
[Abstract] Objective To explore and analyze clinical effects and safety of Urinary Kallidinogenase in treatment of acute progressive cerebral infarction. Methods 180 patients with acute progressive cerebral infarction who were admitted to our hospital were selected as research objects and they were allocated to the control group and the study group， with 90 in each. Patients in the control group were received conventional treatment while patients in the study group were received Urinary Kallidinogenase based on conventional treatment. Clinical effects and safety of two groups were compared. Results The neural function defect symptoms score (NIHSS) and activities of daily living (ADL) scores before treatment of the two groups had no significant differences (P>0.05). The NIHSS scores after treatment of the study group was significantly lower than that of the control group but the ADL score in the study group was significantly higher than that of the control group (P<0.05). Total effective rate of the study group was 91.11% which was significantly higher than that of the control group 73.33% (P<0.05). The incidence rates of adverse reactions including increased blood pressure and nausea of patients in two groups were about 5%. They were relieved after symptomatic treatment (P>0.05). Conclusion Application of Urinary Kallidinogenase in the treatment of patients with acute progressive cerebral infarction can effectively correct the neural function defect symptoms and improve their daily activity level. It has an obvious curative effect， less adverse reactions and high safety which is worthy of promotion and application.
, 百拇医药
[Key words] Acute progressive cerebral infarction； Urinary Kallidinogenase； Clinical curative effects； Safety
急性进展性脑梗死指发病6h后患者的局灶性脑缺血症状仍逐渐进展。神经功能损害逐渐加重，是脑梗死患者致残的重要因素[1-2]。随着老龄化的加剧，脑梗死的发病率不断上升[3]。据报道，超过1/3的脑梗死患者会出现进展，而且易引起医患纠纷[4-5]。针对该类患者，积极探索安全有效的治疗方法，具有极为重要的现实意义。如何及时恢复脑血流和保护脑细胞以及清除自由基已成为急性进展性脑梗死患者治疗的关键[6]。激肽原酶能够靶向性启动缺血区侧支循环，从而有效改善脑血流灌注，增加脑缺血区软脑膜血流灌注[7]。我院选择以该元素为主要有效成分的尤瑞克林对患者进行治疗，取得了有价值的临床经验，具体报道如下。, http://www.100md.com(邱凌骐 邱浩强 陈松深)
[关键词] 急性进展性脑梗死；尤瑞克林；临床疗效；安全性
, http://www.100md.com
[中图分类号] R743.33 [文献标识码] B [文章编号] 2095-0616(2015)13-61-04
[Abstract] Objective To explore and analyze clinical effects and safety of Urinary Kallidinogenase in treatment of acute progressive cerebral infarction. Methods 180 patients with acute progressive cerebral infarction who were admitted to our hospital were selected as research objects and they were allocated to the control group and the study group， with 90 in each. Patients in the control group were received conventional treatment while patients in the study group were received Urinary Kallidinogenase based on conventional treatment. Clinical effects and safety of two groups were compared. Results The neural function defect symptoms score (NIHSS) and activities of daily living (ADL) scores before treatment of the two groups had no significant differences (P>0.05). The NIHSS scores after treatment of the study group was significantly lower than that of the control group but the ADL score in the study group was significantly higher than that of the control group (P<0.05). Total effective rate of the study group was 91.11% which was significantly higher than that of the control group 73.33% (P<0.05). The incidence rates of adverse reactions including increased blood pressure and nausea of patients in two groups were about 5%. They were relieved after symptomatic treatment (P>0.05). Conclusion Application of Urinary Kallidinogenase in the treatment of patients with acute progressive cerebral infarction can effectively correct the neural function defect symptoms and improve their daily activity level. It has an obvious curative effect， less adverse reactions and high safety which is worthy of promotion and application.
, 百拇医药
[Key words] Acute progressive cerebral infarction； Urinary Kallidinogenase； Clinical curative effects； Safety
急性进展性脑梗死指发病6h后患者的局灶性脑缺血症状仍逐渐进展。神经功能损害逐渐加重，是脑梗死患者致残的重要因素[1-2]。随着老龄化的加剧，脑梗死的发病率不断上升[3]。据报道，超过1/3的脑梗死患者会出现进展，而且易引起医患纠纷[4-5]。针对该类患者，积极探索安全有效的治疗方法，具有极为重要的现实意义。如何及时恢复脑血流和保护脑细胞以及清除自由基已成为急性进展性脑梗死患者治疗的关键[6]。激肽原酶能够靶向性启动缺血区侧支循环，从而有效改善脑血流灌注，增加脑缺血区软脑膜血流灌注[7]。我院选择以该元素为主要有效成分的尤瑞克林对患者进行治疗，取得了有价值的临床经验，具体报道如下。, http://www.100md.com(邱凌骐 邱浩强 陈松深)